Skip to main content
TipRanks
Go Ultimate75% OFF

Nanobiotix (NANO) Stock Price & Analysis

37 Followers

NANO Stock Chart & Stats

€27.90-€1.14(-3.93%)
At close: 5:30 PM GMT+1
€20€25€30€35Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
EUR 27.28 - EUR 29.00
52-Week Range
EUR 16.52 - EUR 47.66
Previous Close
EUR 29.04
Volume
N/A
Average Volume (3M)
211.17K
Market Cap
EUR 1.42B
Enterprise Value
EUR 1.56B
Total Cash (Recent Filing)
EUR 110.89M
Total Debt (Recent Filing)
EUR 106.61M
Price to Earnings (P/E)
―
Beta
0.52
Next Earnings
Apr 27, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Nanoparticle Oncology Platform

The NBTXR3 platform gives Nanobiotix a differentiated technology focus within oncology, where improving the effectiveness of established radiotherapy could support multiple solid-tumor applications. If clinical development succeeds, the platform approach may create broader growth potential than a single-indication therapy.

2025 Revenue Growth

The sharp 2025 revenue increase indicates that the company has demonstrated some ability to generate commercial or partnership-related top-line activity after an inconsistent prior period. Continued conversion of development progress into revenue could improve operating leverage and support longer-term funding capacity.

High Gross Margin

A 100% gross margin suggests that reported 2025 revenue carried substantial contribution before operating expenses, leaving theoretical room for future profitability if revenue becomes more stable and scales. This is a potentially favorable economic feature, although it has not yet offset the company’s development spending.

Bears Say

Persistent Losses

Persistent operating and net losses show that Nanobiotix has not yet established repeatable earnings power. Continued deficits can constrain strategic flexibility and require additional financing, while the absence of demonstrated profitability makes future results highly dependent on successful clinical and commercial execution.

Ongoing Cash Burn

Consistently negative operating and free cash flow means reported activity is not currently funding the business internally. Although 2025 cash burn was lower than the prior year, the company still consumes cash, which can force reliance on external capital and limit its ability to sustain development independently.

Negative Equity And Rising Debt

Negative shareholders’ equity materially weakens the balance sheet and reduces financial flexibility, while higher debt increases the burden on a company that is already loss-making and cash-burning. This capital structure can make future funding more difficult and heightens sensitivity to financing requirements.

Nanobiotix News

NANO FAQ

What was Nanobiotix’s price range in the past 12 months?
Nanobiotix lowest stock price was €16.52 and its highest was €47.66 in the past 12 months.
What is Nanobiotix’s market cap?
Nanobiotix’s market cap is €1.42B.
When is Nanobiotix’s upcoming earnings report date?
Nanobiotix’s next earnings report is estimated for Apr 27, 2027 (not yet confirmed), which is in 162 days.
How were Nanobiotix’s earnings last quarter?
Nanobiotix released its earnings results on Sep 24, 2026. The company reported -€0.7 earnings per share for the quarter, missing the consensus estimate of -€0.25 by -€0.45.
Is Nanobiotix overvalued?
According to Wall Street analysts Nanobiotix’s price is currently Undervalued.
Does Nanobiotix pay dividends?
Nanobiotix does not currently pay dividends.
What is Nanobiotix’s EPS estimate?
Nanobiotix’s EPS estimate is 0.05.
How many shares outstanding does Nanobiotix have?
Nanobiotix has 50,967,610 shares outstanding.
What happened to Nanobiotix’s price movement after its last earnings report?
Nanobiotix reported an EPS of -€0.7 in its last earnings report, missing expectations of -€0.25. Following the earnings report the stock price went up 4.366%.
Which hedge fund is a major shareholder of Nanobiotix?
Currently, no hedge funds are holding shares in FR:NANO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology